Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
How It Works 
News - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- About
Kiniksa Pharmaceuticals Ltd(KNSA)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for KNSA
09/14/2026: KNSA (2-star) has a low Upturn Star Rating. Not recommended to BUY.
Kiniksa Pharmaceuticals is a biopharmaceutical company focused on developing therapies for debilitating autoimmune and inflammatory diseases. Its primary value driver is ARCALYST, an FDA-approved treatment that provides a consistent revenue stream and has established the company's commercial capabilities. While its pipeline offers potential for long-term growth through candidate expansion, Kiniksa remains dependent on its lead asset, which presents a significant product concentration risk. The company is best suited for growth-oriented investors who are comfortable with the inherent volatility of clinical-stage biotechnology. Key developments to monitor include upcoming clinical trial readouts for vixarelimab and the continued commercial penetration of ARCALYST into underserved patient populations.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Strong fit | The company is in an active growth phase driven by the commercial ramp-up of its primary product and potential pipeline breakthroughs. |
| Momentum investor | Mixed fit | Momentum suitability is conditional on positive clinical data readouts or strong quarterly sales growth that exceed market expectations. |
| Value investor | Weak fit | As a loss-making biotech firm, the company is valued on future growth potential rather than current earnings or book value. |
| Dividend investor | Weak fit | The company does not pay a dividend and is unlikely to do so in the near future given its stage of development. |
| Low-risk investor | Weak fit | Biotechnology stocks are inherently high-risk due to clinical trial volatility and regulatory uncertainty. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | Clinical trial results and regulatory decisions can lead to sharp, unpredictable swings in the stock price. |
| Valuation risk | Medium / high | The stock price is heavily reliant on future success, making it sensitive to shifts in growth expectations. |
| Competition risk (Pharmaceutical) | Medium / high | Larger companies with more resources could introduce competing therapies that undermine Kiniksa's market position. |
| Business quality | Medium | While the company has a successful product, its overall quality is still maturing as it works to diversify its revenue base. |
| Dividend income | Low / none | Investors should not expect income from this equity as capital is prioritize for R&D. |
| Execution risk | Medium / high | Successfully managing the commercialization and clinical pipeline requires precise operational execution. |
Price Behavior
Strong Uptrend
The stock has maintained a strong upward price trend across the last three quarters.
Choppy
The stock has experienced frequent reversals and pronounced short-term price swings.
Analysis of Past Performance
Type Stock | Historic Profit -6.12% | Avg. Invested days 41 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Advisory Rating  | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/14/2026 |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals
Financial Health Rating
Growth Momentum Score
Ownership
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue)
Economic Dimensions
Quantitative Style Profile
Style Classification
Quality Focused
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 5.98B USD | Price to earnings Ratio 77.35 | 1Y Target Price 98 |
Price to earnings Ratio 77.35 | 1Y Target Price 98 | ||
Volume (30-day avg) 472.5K shares | Beta 0.09 | 52 Weeks Range 35.20 - 82.94 | Updated Date 09/14/2026 |
52 Weeks Range 35.20 - 82.94 | Updated Date 09/14/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) 0.99 |
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Commercial Pharmaceuticals | Revenue generated from the sales of ARCALYST in the United States. | The company primarily earns money from selling a single drug to treat specific rare, inflammatory conditions. |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Valuation
Trailing PE 77.35 | Forward PE 59.52 | Enterprise Value 5.43B | Price to Sales(TTM) 7.11 |
Enterprise Value 5.43B | Price to Sales(TTM) 7.11 | ||
Enterprise Value to Revenue 6.45 | Enterprise Value to EBITDA 53.18 | Shares Outstanding 48.29M | Shares Floating 39.86M |
Shares Outstanding 48.29M | Shares Floating 39.86M | ||
Percent Insiders 3.51 | Percent Institutions 100.84 |
Upturn AI Summary
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.
About Kiniksa Pharmaceuticals Ltd
Exchange NASDAQ | Headquarters - | ||
IPO Launch date 2018-05-24 | CEO & Chairman of the Board Mr. Sanjiv K. Patel | ||
Sector Healthcare | Industry Drug Manufacturers - Specialty & Generic | Full time employees 366 | Website https://www.kiniksa.com |
Full time employees 366 | Website https://www.kiniksa.com | ||
Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, develops and commercializes medical therapies in the United States, the United Kingdom, and internationally. The company offers ARCALYST, an interleukin-1alpha and 1beta cytokine trap for the treatment of recurrent pericarditis, a chronic autoinflammatory cardiovascular disease and cardiac sarcoidosis. It also develops KPL-387, an investigational and fully human immunoglobulin G2 monoclonal antibody, which is Phase 2/3 clinical trial for the treatment of recurrent pericarditis; and KPL-116, a Fc-modified immunoglobulin G2 monoclonal antibody, which is in pre-clinical stage. The company was formerly known as Kiniksa Pharmaceuticals, Ltd. and changed its name to Kiniksa Pharmaceuticals International, plc in June 2024. Kiniksa Pharmaceuticals International, plc was incorporated in 2015 and is based in London, the United Kingdom.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.